Dorsavi Ltd. · ASX:DVL
Dorsavi — Investor Presentation (February 2018)
26 slides from Dorsavi's investor presentation, Feb 7, 2018
Slide 1: Inspiring the World to Move Well - Investor Update February 2018
For personal use only INSPIRING THE WORLD TO MOVE WELL INVESTOR UPDATE FEBRUARY 2018
Slide 2: Investment Highlights
// 2 INVESTMENT HIGHLIGHTS • First mover advantage, leader with medical grade wearable technology – FDA, CE Mark, TGA approved • Three attractive markets – Occupational Health & Safety, Clinical, and Elite Sports For personal use only • Across three geographic markets – US, UK and Australia • Contin
Slide 3: Strong Foundation for Growth
// 3 STRONG FOUNDATION FOR GROWTH • Patent protected algorithms on medical- For personal use only grade sensor technology • OHS solution to determine, measure and mitigate high risk activities • Significant barriers to entry and limited • Executive and board-level focus on reducing injuries and comp
Slide 4: Q2/H1 Financial Overview
// 4 Q2/H1 FINANCIAL OVERVIEW 2015 2016 2017 H1 2018* For personal use only Revenue 1,358,218 3,019,928 3,466,027 1,949,000 EBITDA (8,851,345) (5,928,797) (4,691,358) N/A Loss from continuing (8,036,161) (5,237,102) (3,876,248) N/A operations Cash position $5.74M $6.03M $8.61M $6.75M * unaudited res
Slide 5: H1 FY18 Milestones & Upcoming Plans
H1 FY18 MILESTONES & UPCOMING PLANS // 5 MILESTONES PLANS For personal use only Q2 MILESTONES PLANS FOR Q3 PLANS FOR Q4 Jul 2017 Oct 2017 Jan 2018 Q4 FY18 ViMove™ used to Success in the Operational changes to drive US Launch of new clinical validate patient aged care sector market penetration. produ
Slide 6: Business Evolution to Drive Scale
// 6 BUSINESS EVOLUTION TO DRIVE SCALE 1. Operational structure to drive growth • CEO and Founder Dr Andrew Ronchi relocated to US For personal use only • General Manager appointed 2. Product and marketing initiatives to meet market needs • Clinical: ViMove2 launch in Australia and UK completed succ
Slide 7: 1. Operational Changes to Drive Growth
// 7 1. OPERATIONAL CHANGES TO For personal use only DRIVE GROWTH
Slide 8: 1. Operational Changes to Drive Growth
// 8 1. OPERATIONAL CHANGES TO DRIVE GROWTH • Focus has been on product optimisation, building a solid foundation of large For personal use only customers and creating the right structure for growth: Establishing revenue model to build annuity revenue Sales model & product to penetrate key markets m
Slide 9: Matt May – General Manager
// 9 Matt May – General Manager • For personal use only Matt May, former Head of Sales and Operations for Australia, promoted to General Manager: • Experienced operations executive and has led dorsaVi’s Australian sales and operations since 2014. • Experience in both clinical and workplace; with cus
Slide 10: 2. Product and Marketing Initiatives to Meet Market Needs
// 10 2. PRODUCT AND MARKETING For personal use only INITIATIVES TO MEET MARKET NEEDS
Slide 11: 2. Product Evolution to Meet Market Needs
// 11 2. PRODUCT EVOLUTION TO MEET MARKET NEEDS For personal use only Benefits of new tech platform: • 10 second start up (vs 3 mins) • Significant reduction in COGS • Training 10 min call (vs 4 hrs F2F) • Smaller and lighter • Higher data rates • Mobile use case (remote) • Sell on line • Scalable f
Slide 12: Key Features – Clinical ViMove2
// 12 KEY FEATURES – Clinical ViMove2 FAST AND INTERACTIVE TABLET SYSTEM For personal use only • Intuitive software • Flexible platform for multiple markets/opportunities ENHANCED PATIENT RELATIONSHIP • Patient App delivering: • Unique insights • Reports and exercises NEW REVENUE OPPORTUNITIES • In
Slide 13: Aligning with Industry Experts
// 13 ALIGNING WITH INDUSTRY EXPERTS For personal use only
Slide 14: Sales & Marketing Update - Clinical
// 14 SALES & MARKETING UPDATE - CLINICAL For personal use only • Objectives • Remove perceived ‘big decision’ barriers • Shorten sales cycle • Reduce sales involvement • Move devices in higher volume • Build critical mass to allow us to start push/pull marketing • Tactics • Regular campaigns with p
Slide 15: Planning for the US Clinical Launch
// 15 PLANNING FOR THE US CLINICAL LAUNCH US CLINICAL MARKET For personal use only • What we know and will keep doing: • Continue to utilise existing reimbursement codes with average billing of $150 per session • Continue to build relationships with large clinical groups like Select Medical • Expand
Slide 16: Key Offerings to the OHS Market
// 16 KEY OFFERINGS TO THE OHS MARKET For personal use only & • Reduce workplace injury risk • Improve productivity • Increase compliance • Workers compensation savings • Enhance safety culture
Slide 17: Large Consulting Projects in House Monitoring Platform
// 17 LARGE CONSULTING PROJECTS IN HOUSE MONITORING PLATFORM For personal use only Data Centralised gathered Data out in the field For Manager/Executive Employee Supervisor
Slide 18: Sales & Marketing Update - Workplace
// 18 SALES & MARKETING UPDATE - WORKPLACE For personal use only • Objectives • Increase awareness in key industries • Leverage existing customer success to accelerate market adoption • Profile industry role models • Increase annuity revenue • Up-sell existing customers (ViSafe to myViSafe) • Tactic
Slide 19: For personal use only
// 19 For personal use only https://dorsavi.adobeconnect.com/pa3l8r5cggpg/
Slide 20: 3. Growing Annuity Revenue Toward SaaS Model
// 20 For personal use only 3. GROWING ANNUITY REVENUE TOWARD SaaS MODEL (Clinical & Workplace)
Slide 21: 3. Capturing the US Clinical Market
// 21 3. CAPTURING THE US CLINICAL MARKET dorsaVi clinical sites and number of PTs in larger states • Business model ‘up front’ hardware purchase For personal use only and ongoing software fees • Very high customer retention rate • dorsaVi in >200 sites across the US • Large US market with 284,000 p
Slide 22: In House Monitoring Platform (myViSafe)
// 22 LARGE CONSULTING PROJECTS IN HOUSE MONITORING PLATFORM For personal use only • Self managed solution to monitor employee movement • Strong repeat business from major brands • Accessible to all organisations with >100 employees • Trend in moving to annuity model & self managed • Attractive pric
Slide 23: 4. Strategic Relationships with Global Leaders
// 23 4. STRATEGIC RELATIONSHIPS For personal use only WITH GLOBAL LEADERS
Slide 24: Strategic Relationships with Global Leaders
// 24 STRATEGIC RELATIONSHIPS WITH GLOBAL LEADERS For personal use only MAJOR CLINICAL MEDICAL DEVICES PHARMACEUTICALS UNIVERSITIES GROUPS • Large companies with a • Independent evidence on • Aiming to reduce • Develop better treatment special interest in how their drugs are admissions protocols mov
Slide 25: Outlook
// 25 OUTLOOK For personal use only • US Launch of new clinical product in Q4 FY2018 • Focus on large clinical groups • Expand myViSafe market through partnerships with insurers • Secure deals with strategic partners searching for movement related solutions
Slide 26: dorsaVi Contact Details
// 26 dorsaVi™ For personal use only Andrew Ronchi PhD (Eng), B.App.Sci (Physio) Chief Executive Officer Level 1, 120 Jolimont Road, East Melbourne, Victoria 3002 Office: +61 9652 2192 | Mobile: +61 417 882 267 ar@dorsaVi.com | dorsaVi.com